IGALMI
Total Payments
$8.7M
Transactions
5,309
Doctors
2,768
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $4.7M | 568 | 384 |
| 2023 | $4.0M | 4,741 | 2,480 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.5M | 62 | 86.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $455,983 | 184 | 5.3% |
| Consulting Fee | $420,398 | 52 | 4.8% |
| Food and Beverage | $159,119 | 4,205 | 1.8% |
| Travel and Lodging | $91,244 | 794 | 1.1% |
| Honoraria | $12,690 | 12 | 0.1% |
Payments by Type
Research
$7.5M
62 transactions
General
$1.1M
5,247 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA | BioXcel Therapeutics, Inc. | $2.3M | 0 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY ANDSAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD INSUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEASTMODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING | BioXcel Therapeutics, Inc. | $2.0M | 0 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEAST MODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING | BioXcel Therapeutics, Inc. | $1.5M | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 OF AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER | BioXcel Therapeutics, Inc. | $1.2M | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER | BioXcel Therapeutics, Inc. | $448,946 | 0 |
| EVALUATION OF BXCL501 PLACEBO INSTRUCTIONS FOR USE AND COMPREHENSION OF TRAINING FOR CAREGIVERS AND PARTICIPANTS WITH AGITATION ASSOCIATED WITH ALZHEIMERS DEMENTIA PARTICIPATING IN STUDIES INVESTIGATING AT-HOME ADMINISTRATION | BioXcel Therapeutics, Inc. | $91,092 | 0 |
Top Doctors Receiving Payments for IGALMI — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Psychiatry | Elmhurst, NY | $241.56 | 2 |
| , M.D | Psychiatry | Staunton, VA | $240.56 | 5 |
| , MD | Pediatrics | Newark, NJ | $239.87 | 3 |
| , DO | Emergency Medicine | Jersey City, NJ | $239.87 | 3 |
| , M.D | Psychiatry | Las Vegas, NV | $233.95 | 4 |
| , M.D | Mental Health | Las Vegas, NV | $233.95 | 4 |
| , MD | Psychiatry | Brooklyn, NY | $230.71 | 10 |
| , M.D | Infectious Disease | New York, NY | $228.78 | 2 |
| , DO | Emergency Medicine | Arlington, VA | $224.67 | 2 |
| , MD | Emergency Medicine | Reston, VA | $224.67 | 2 |
| , MD | Emergency Medicine | Germantown, MD | $224.67 | 2 |
| , MD | Emergency Medicine | Reston, VA | $224.67 | 2 |
| , M.D | Internal Medicine | Ashburn, VA | $224.67 | 2 |
| , APRN | Psychiatric/Mental Health | Las Vegas, NV | $222.92 | 8 |
| , MD | Neurology | Brooklyn, NY | $221.75 | 8 |
| , PA | Physician Assistant | Branchburg, NJ | $214.87 | 4 |
| , APRN | Adult Health | Longwood, FL | $210.96 | 5 |
| , PA-C | Medical | Grosse Pointe Woods, MI | $204.25 | 1 |
| , M.D | Emergency Medicine | Peoria, IL | $203.17 | 4 |
| , NP | Acute Care | Lebanon, IN | $202.78 | 3 |
| , M.D | Psychiatry | Brooklyn, NY | $197.87 | 9 |
| , DO | Emergency Medicine | Livingston, NJ | $197.03 | 4 |
| , MD | Emergency Medicine | Livingston, NJ | $197.03 | 4 |
| , PMHNP-BC | Psychiatric/Mental Health | Hyannis, MA | $196.95 | 2 |
| , MD | Psychosomatic Medicine | Whitefish Bay, WI | $196.95 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $8.7M
- Total Doctors 2,768
- Transactions 5,309
About IGALMI
IGALMI is a drug associated with $8.7M in payments to 2,768 healthcare providers, recorded across 5,309 transactions in the CMS Open Payments database. The primary manufacturer is BioXcel Therapeutics, Inc..
Payment data is available from 2023 to 2024. In 2024, $4.7M was paid across 568 transactions to 384 doctors.
The most common payment nature for IGALMI is "Unspecified" ($7.5M, 86.9% of total).
IGALMI is associated with 6 research studies, including "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA" ($2.3M).